| Dr Debra L Powell, MD | |
|
301 S 7th Ave, Suite 130, West Reading, PA 19611-1410 | |
| (484) 628-4630 | |
| (610) 374-8324 |
| Full Name | Dr Debra L Powell |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 21 Years |
| Location | 301 S 7th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649483272 | NPI | - | NPPES |
| 126412 | Other | PA | MEDICARE ID |
| 102165835 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MD433966 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Reading Hospital | 7618886490 | 102 |
News Archive
This post in the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, part of a six-part series of blog posts covering interesting elements of the Nicaragua experience highlighted in the case study entitled "Worms and WASH(ED)," examines how the country's "history in ensuring a national deworming program has shed light on the potential for success."
The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).
› Verified 6 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
This post in the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, part of a six-part series of blog posts covering interesting elements of the Nicaragua experience highlighted in the case study entitled "Worms and WASH(ED)," examines how the country's "history in ensuring a national deworming program has shed light on the potential for success."
The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).
› Verified 6 days ago
| Entity Name | Reading Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992387518 PECOS PAC ID: 7618886490 Enrollment ID: O20040408001076 |
News Archive
This post in the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, part of a six-part series of blog posts covering interesting elements of the Nicaragua experience highlighted in the case study entitled "Worms and WASH(ED)," examines how the country's "history in ensuring a national deworming program has shed light on the potential for success."
The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Debra L Powell, MD 301 S 7th Ave, West Reading, PA 19611-1410 Ph: (484) 628-4630 | Dr Debra L Powell, MD 301 S 7th Ave, Suite 130, West Reading, PA 19611-1410 Ph: (484) 628-4630 |
News Archive
This post in the Global Network for Neglected Tropical Diseases' "End the Neglect" blog, part of a six-part series of blog posts covering interesting elements of the Nicaragua experience highlighted in the case study entitled "Worms and WASH(ED)," examines how the country's "history in ensuring a national deworming program has shed light on the potential for success."
The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).
› Verified 6 days ago
Ankush Lahoti, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, Suite 2020, West Reading, PA 19611 Phone: 610-375-6565 Fax: 610-375-2065 | |
Tayyab Ali Waheed, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Nyein Yu, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-5455 | |
Richard Loynd, D.O. Infectious Disease Medicare: Medicare Enrolled Practice Location: 6th Avenue And Spruce Street, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Krysta Brown, DO Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave Ste 340, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Niranjan Tachamo, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-5455 | |
Earl J Hope, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, Suite 2020, West Reading, PA 19611 Phone: 610-375-6565 Fax: 610-375-2065 |